TABLE 2.
Hematopoietic stem cell transplantation (HSCT) management and outcomes of the 12 high-risk patients.
| Patients | HLA match | Source | MNC (×107 cells/kg for CB; 108 cells/kg for PBSC) | Conditioning regimen | Day ANC > 500 | GVHD prophylaxis | Donor chimerism (%) | GVHD (acute/chronic) | Status |
| 2 | 10-Oct | PBSC, sibling | 10.5 | TBI 9Gy – Cy-VP-16- semustine | 11 | CsA + MMF + MTX | 100 | No/No | Disease free and alive |
| 4 | 10-Oct | PBSC, sibling | 10.3 | TBI 9Gy – Cy-VP-16- semustine | 12 | CsA + MMF + MTX | 100 | No/Yes | Disease free and alive |
| 8 | 10-Oct | CB | 3.7 | Bu-Cy-Flu-TBI 14.4Gy | 17 | CsA + MMF | 100 | Yes/Yes | alive |
| 9 | 09-Oct | CB | 9.1 | Bu-Cy-Flu- semustine | 17 | CsA + MMF | 100 | Yes/No | Disease free and alive |
| 12 | 07-Oct | CB | 5 | Bu-Cy-Flu-Dec- semustine | 19 | CsA + MMF | 100 | Yes/Yes | Relapsed and dead |
| 16 | 08-Oct | CB | 3.3 | Bu-Cy-Cla-Ara-C- semustine | 22 | CsA + MMF | 100 | Yes/Yes | Disease free and alive |
| 18 | 09-Oct | CB | 4 | Bu-Cy-Cla-Ara-C- semustine | 14 | CsA + MMF | 100 | Yes/No | Disease free and alive |
| 19 | 08-Oct | CB | 4.7 | Bu-Cy-Cla-Ara-C- semustine | 17 | CsA + MMF | 100 | Yes/Yes | Disease free and alive |
| 21 | 09-Oct | PBSC, unrelated | 11.3 | Cy-ATG-VP-16- semustine | 14 | CsA + MMF + MTX | 100 | Yes/No | Disease free and alive |
| 24 | 08-Oct | CB | 3.8 | Bu-Cy-Cla-Ara-C- semustine | 18 | CsA + MMF | 100 | Yes/No | Disease free and alive |
| 26 | 09-Oct | PBSC MMUD |
12.67 | Cy-ATG-VP-16- semustine | 11 | CsA + MMF + MTX | 100 | Yes/Yes | Disease free and alive |
| 27 | 07-Oct | BM + PBSC Haploid father | 11.6 | Bu-Cy-ATG-Cla-Ara-C- semustine | 13 | CsA + MMF + MTX | 100 | Yes/No | Disease free and alive |
ANC.500, absolute neutrophil count.500/mm3; Ara-C, cytarabine; ATG, antithymocyte globulin; BM, bone marrow stem cell graft; Bu, busulfan; CB, cord blood stem cell graft; Cla, cladribine; CsA, cyclosporin A; Cy, cyclophosphamide; Flu, fludarabine; GVHD, graft versus host disease; haplo-id, haplo-identical donor; MMF, mycophenolate mofetil; MNC, mononuclear cell count; MTX, methotrexate; PBSC, peripheral blood stem cells; TBI, total body irradiation; VP-16, etoposide.